FSCN1 and cancer: Since FSCN1 overexpression has been correlated with poor clinical outcomes and shorter survival across different cancer types, FSCN1 has been suggested as a therapeutic target for blocking migration, invasion and metastasis, encouraging FSCN1 inhibitors identification [57].